The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Adverse Events Associated with Testosterone Administration
Open accessAbstract
BACKGROUND: Testosterone supplementation has been shown to increase muscle mass and strength in healthy older men. The safety and efficacy of testosterone treatment in older men who have limitations in mobility have not been studied. METHODS: Community-dwelling men, 65 years of age or older, with limitations in mobility and a total serum testosterone level of 100 to 350 ng per deciliter (3.5 to 12.1 nmol per liter) or a free serum testosterone level of less than 50 pg per milliliter (173 pmol per liter) were randomly assigned to receive placebo gel or testosterone gel, to be applied daily for 6 months. Adverse events were categorized with the use of the Medical Dictionary for Regulatory Activities classification. The data and safety monitoring board recommended that the trial be discontinued early because there was a significantly higher rate of adverse cardiovascular events in the testosterone group than in the placebo group. RESULTS: A total of 209 men (mean age, 74 years) were enrolled at the time the trial was terminated. At baseline, there was a high prevalence of hypertension, diabetes, hyperlipidemia, and obesity among the participants. During the course of the study, the testosterone group had higher rates of cardiac, respiratory, and dermatologic events than did the placebo group. A total of 23 subjects in the testosterone group, as compared with 5 in the placebo group, had cardiovascular-related adverse events. The relative risk of a cardiovascular-related adverse event remained constant throughout the 6-month treatment period. As compared with the placebo group, the testosterone group had significantly greater improvements in leg-press and chest-press strength and in stair climbing while carrying a load. CONCLUSIONS: In this population of older men with limitations in mobility and a high prevalence of chronic disease, the application of a testosterone gel was associated with an increased risk of cardiovascular adverse events. The small size of the trial and the unique population prevent broader inferences from being made about the safety of testosterone therapy. (ClinicalTrials.gov number, NCT00240981.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current evidence consistently shows that untreated low testosterone levels are associated with an increased risk of MACE”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Changes in fat mass, lean body mass, and muscle strength occur within 12–16 weeks, stabilize at 6–12 months, but can marginally continue over years.”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, T supplementation is not without risk and could potentially be harmful concerning cardiovascular risk in the elderly [248].”
From Role of sex hormone-binding globulin in the free hormone hypothesis and the relevance of free testosterone in androgen physiology (2022) · cites this paper as [248]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have previously reported that testosterone levels are linked to a variety of conditions and diseases, such as cardiovascular disease, type-2 diabetes, the metabolic syndrome, erectile dysfunction, depression, obesity, stroke and osteoporosis. 1-7”
From Cigarette smoking has a positive and independent effect on testosterone levels (2013) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“studies that measure cardiovascular benefit or harm in men on testosterone therapy have returned inconsistent and controversial results.”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [41]
The cited source says what the claim attributes to it.
In the citing paper
“the current scientific literature does not definitively demonstrate that testosterone therapy increases the risk of MACE.”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [41]
The cited source says what the claim attributes to it.
In the citing paper
“and that testosterone administration can increase the risk of cardiovascular adverse events as well. 7”
From Cigarette smoking has a positive and independent effect on testosterone levels (2013) · cites this paper as [7]
In the citing paper
“Low vitamin D levels have been associated with frailty (133)”
From Frailty in elderly people (2013) · cites this paper as [133]
In the citing paper
“Additionally, testosterone replacement is not without potential risks, including increased respiratory disorders (eg, cough, shortness of breath, asthma or chronic obstructive pulmonary disease (COPD) exacerbation, sleep apnoea) and skin and subcutaneous tissue disorders (eg, application site reactions, itching, erythema, foot ulcers, and increased hair growth).84”
From Age-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases (2014) · cites this paper as [84]
In the citing paper
“preventing an age-related decline in hormones by exogenous replacement is associated with increased risk for adverse effects in older adults.11-13”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [13]
In the citing paper
“Unfortunately, hormone replacement therapy is not a panacea, as it often results in various adverse events which outweigh its potential health benefits.”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [13]
In the citing paper
“Some of the risks associated with T therapy include exacerbation of prostate cancer, cardiovascular-related events, hepatotoxicity, erythrocytosis, sleep apnea, and dermatological issues.12, 13”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [13]
In the citing paper
“Serum hepcidin was measured by enzyme-linked immunosorbent assay (Intrinsic Life Sciences) with sensitivity of 5 ng/mL, interassay coefficient of variation 12%, and range 29-254 ng/ mL in men (12,15).”
From Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point (2014) · cites this paper as [12]
In the citing paper
“We have reported that administration of supraphysiologic doses of testosterone in healthy men suppresses the iron regulatory peptide hepcidin while EPO levels remained unchanged after 20 weeks of treatment (12).”
From Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point (2014) · cites this paper as [12]
In the citing paper
“We also show that testosterone administration is associated with lower hepcidin levels in older men with mobility limitation and high burden of chronic diseases, confirming our previous observations in healthy younger and older men and demonstrating a similar magnitude of hepcidin suppression (12).”
From Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point (2014) · cites this paper as [12]
In the citing paper
“It can be concluded that the effects of testosterone on muscle strength are demonstrable after 12–20 weeks and that depending on the achieved testosterone levels, the maximum effects are attained after 6 or 12 months.”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [16]
In the citing paper
“Another study using high doses of testosterone gel (starting dose 100 mg/day with possible up-titration to 150 mg/day) observed significant increases in leg press strength, chest press strength, and stair climbing power with a load within 6 months (16).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability
Guralnik, J. M., Ferrucci, L., Simonsick, E. M., Salive, M. E., & Wallace, R. B. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503023320902 · Cited by 4,083
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationThe effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T. J., Tricker, R., Shirazi, A., & Casaburi, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350101 · Cited by 1,659
Self-citationFried, L. P. (1998) · JAMA · doi:10.1001/jama.279.8.585 · Cited by 1,107
Newman, A. B., Simonsick, E. M., Naydeck, B. L., Boudreau, R. M., Kritchevsky, S. B., Nevitt, M. C., Pahor, M., Satterfield, S., Brach, J. S., Studenski, S. A., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2018 · Cited by 934
Testosterone Replacement in Older Hypogonadal Men: A 12-Month Randomized Controlled Trial
Sih, R., Morley, J. E., Kaiser, F. E., Perry, H. M., Patrick, P., & Ross, C. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.6.3988 · Cited by 920
Associations of Subclinical Cardiovascular Disease With Frailty
Newman, A. B., Gottdiener, J. S., McBurnie, M. A., Hirsch, C. H., Kop, W. J., Tracy, R. P., Walston, J. D., & Fried, L. P. (2001) · The Journals of Gerontology Series A · doi:10.1093/gerona/56.3.m158 · Cited by 813
Predictors of skeletal muscle mass in elderly men and women
Baumgartner, R. N., Waters, D. L., Gallagher, D., Morley, J. E., & Garry, P. J. (1999) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(98)00130-4 · Cited by 809
Low Serum Testosterone and Mortality in Older Men
Laughlin, G. A., Barrett-Connor, E., & Bergstrom, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1792 · Cited by 798
Effects of testosterone supplementation in the aging male
Tenover, J. S. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.4.1092 · Cited by 768
Research works printed but not linked: 1
- 10.1210/jc.82.6.1661 · DOI
Cited by
Sorted by citations
Clegg, A., Young, J., Iliffe, S., Rikkert, M. O., & Rockwood, K. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62167-9 · Cited by 9,503
A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans
Morley, J. E., Malmstrom, T. K., & Miller, D. K. (2012) · The journal of nutrition health & aging · doi:10.1007/s12603-012-0084-2 · Cited by 2,082
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00229 · Cited by 1,736
Self-citationSarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382
Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation
Hatzimouratidis, K., Amar, E., Eardley, I., Giuliano, F., Hatzichristou, D., Montorsi, F., Vardi, Y., & Wespes, E. (2010) · European Urology · doi:10.1016/j.eururo.2010.02.020 · Cited by 1,223
Age-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases
Kalyani, R. R., Corriere, M., & Ferrucci, L. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70034-8 · Cited by 1,102
Leng, S. X., Chen, X., & Mao, G. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s45300 · Cited by 1,066
Vigen, R. (2013) · JAMA · doi:10.1001/jama.2013.280386 · Cited by 1,003
Effects of Testosterone Treatment in Older Men
Snyder, P. J., Bhasin, S., Cunningham, G. R., Matsumoto, A. M., Stephens-Shields, A. J., Cauley, J. A., Gill, T. M., Barrett-Connor, E., Swerdloff, R. S., Wang, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506119 · Cited by 890
Self-citationInflammatory markers in population studies of aging
Singh, T., & Newman, A. B. (2010) · Ageing Research Reviews · doi:10.1016/j.arr.2010.11.002 · Cited by 866
Estrogens and androgens in skeletal physiology and pathophysiology
Almeida, M., Laurent, M. R., Dubois, V., Claessens, F., O'Brien, C. A., Bouillon, R., Vanderschueren, D., & Manolagas, S. C. (2017) · Physiological Reviews · doi:10.1152/physrev.00033.2015 · Cited by 860
Evaluation and Management of Testosterone Deficiency: AUA Guideline
Mulhall, J. P., Trost, L. W., Brannigan, R. E., Kurtz, E. G., Redmon, J. B., Chiles, K. A., Lightner, D. J., Miner, M. M., Murad, M. H., Nelson, C. J., et al. (2018) · Journal of Urology · doi:10.1016/j.juro.2018.03.115 · Cited by 766
Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men
Finkle, W. D., Greenland, S., Ridgeway, G. K., Adams, J. L., Frasco, M. A., Cook, M. B., Fraumeni, J. F., & Hoover, R. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085805 · Cited by 735
“[4] This was followed by a meta-analysis of a number of a number of very small trials in predominantly older men which also suggested excess cardiovascular risk.”
BackgroundMethodSarcopenia Definition: The Position Statements of the Sarcopenia Definition and Outcomes Consortium
Bhasin, S., Travison, T. G., Manini, T. M., Patel, S., Pencina, K. M., Fielding, R. A., Magaziner, J. M., Newman, A. B., Kiel, D. P., Cooper, C., et al. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16372 · Cited by 723
Self-citationXu, L., Freeman, G., Cowling, B. J., & Schooling, C. M. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-108 · Cited by 569
Horizon scan of global conservation issues for 2011
Sutherland, W. J., Bardsley, S., Bennun, L., Clout, M. N., Côté, I. M., Depledge, M. H., Dicks, L. V., Dobson, A. P., Fellman, L., & Fleishman, E. (2010) · Trends in Ecology & Evolution · doi:10.1016/j.tree.2010.11.002 · Cited by 558
Jones, T. H., Arver, S., Behre, H. M., Buvat, J., Meuleman, E., Moncada, I., Morales, A. M., Volterrani, M., Yellowlees, A., Howell, J. D., et al. (2011) · Diabetes Care · doi:10.2337/dc10-1233 · Cited by 548
Sex differences in lipid and lipoprotein metabolism
Palmisano, B. T., Zhu, L., Eckel, R. H., & Stafford, J. M. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.05.008 · Cited by 551
Osteosarcopenia: where bone, muscle, and fat collide
Hirschfeld, H. P., Kinsella, R., & Duque, G. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4151-8 · Cited by 545
A Systematic Review of the Association Between Erectile Dysfunction and Cardiovascular Disease
Gandaglia, G., Briganti, A., Jackson, G., Kloner, R. A., Montorsi, F., Montorsi, P., & Vlachopoulos, C. V. (2013) · European Urology · doi:10.1016/j.eururo.2013.08.023 · Cited by 522
Cardiovascular Safety of Testosterone-Replacement Therapy
Lincoff, A. M., Bhasin, S., Flevaris, P., Mitchell, L. M., Basaria, S. S., Boden, W. E., Cunningham, G. R., Granger, C. B., Khera, M., Thompson, I. M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2215025 · Cited by 514
Self-citationKelly, D. M., & Jones, T. H. (2015) · Obesity Reviews · doi:10.1111/obr.12282 · Cited by 487
Sarcopenia, Cachexia and Aging: Diagnosis, Mechanisms and Therapeutic Options - A Mini-Review
Ali, S., & Garcia, J. M. (2014) · Gerontology · doi:10.1159/000356760 · Cited by 462
Testosterone treatment and mortality in men with low testosterone levels
Shores, M. M., Smith, N. L., Forsberg, C. W., Anawalt, B. D., & Matsumoto, A. M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2591 · Cited by 460
Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study
Corona, G., Rastrelli, G., Monami, M., Guay, A., Buvat, J., Sforza, A., Forti, G., Mannucci, E., & Maggi, M. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0447 · Cited by 435
Bachman, E., Travison, T. G., Basaria, S., Davda, M. N., Guo, W., Li, M., Connor Westfall, J., Bae, H., Gordeuk, V., & Bhasin, S. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glt154 · Cited by 426
Self-citationDalton, J. T., Barnette, K. G., Bohl, C. E., Hancock, M. L., Rodriguez, D., Dodson, S. T., Morton, R. A., & Steiner, M. S. (2011) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-011-0034-6 · Cited by 403
The role of androgens and estrogens on healthy aging and longevity
Horstman, A. M., Dillon, E. L., Urban, R. J., & Sheffield-Moore, M. (2012) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/gls068 · Cited by 396
Muraleedharan, V., Marsh, H., Kapoor, D., Channer, K. S., & Jones, T. H. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0321 · Cited by 389
Cognitive frailty, a novel target for the prevention of elderly dependency
Ruan, Q., Yu, Z., Ma, C., Bao, Z., Li, J., & He, W. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.12.004 · Cited by 392
Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone
Budoff, M. J., Ellenberg, S. S., Lewis, C. E., Mohler, E. R., Wenger, N. K., Bhasin, S., Barrett-Connor, E., Swerdloff, R. S., Stephens-Shields, A., Cauley, J. A., et al. (2017) · JAMA · doi:10.1001/jama.2016.21043 · Cited by 376
Self-citationTournadre, A., Vial, G., Capel, F., Soubrier, M., & Boirie, Y. (2019) · Joint Bone Spine · doi:10.1016/j.jbspin.2018.08.001 · Cited by 375
Testosterone and Cardiovascular Disease
Kloner, R. A., Carson, C., Dobs, A., Kopecky, S., & Mohler, E. R. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.005 · Cited by 371
Wang, C., Jackson, G., Jones, T. H., Matsumoto, A. M., Nehra, A., Perelman, M. A., Swerdloff, R. S., Traish, A., Zitzmann, M., & Cunningham, G. (2011) · Diabetes Care · doi:10.2337/dc10-2339 · Cited by 366
Low Testosterone in Men with Type 2 Diabetes: Significance and Treatment
Grossmann, M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0118 · Cited by 350
Trends in androgen prescribing in the United States, 2001 to 2011
Baillargeon, J., Urban, R. J., Ottenbacher, K. J., Pierson, K. S., & Goodwin, J. S. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.6895 · Cited by 336
Basaria, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61126-5 · Cited by 328
Self-citationSex Steroid Actions in Male Bone
Vanderschueren, D., Laurent, M. R., Claessens, F., Gielen, E., Lagerquist, M. K., Vandenput, L., Börjesson, A. E., & Ohlsson, C. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1024 · Cited by 327
Sex and Gender Differences in Myocarditis and Dilated Cardiomyopathy
Fairweather, D., Cooper, L. T., & Blauwet, L. A. (2013) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2012.07.003 · Cited by 325
Update: Hypogonadotropic Hypogonadism in Type 2 Diabetes and Obesity
Dandona, P., & Dhindsa, S. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2724 · Cited by 313
Isidori, A. M., Buvat, J., Corona, G., Goldstein, I., Jannini, E. A., Lenzi, A., Porst, H., Salonia, A., Traish, A. M., & Maggi, M. (2013) · European Urology · doi:10.1016/j.eururo.2013.08.048 · Cited by 315
Melzer, D. R., Osborne, N. J., Henley, W., Cipelli, R., Young, A., Money, C., McCormack, P., Luben, R., Khaw, K., Wareham, N. J., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.069153 · Cited by 310
Sharma, R., Oni, O. A., Gupta, K., Chen, G., Sharma, M., Dawn, B., Sharma, R., Parashara, D., Savin, V. J., Ambrose, J. A., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv346 · Cited by 306
Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis
Ruige, J. B., Mahmoud, A., Bacquer, D. D., & Kaufman, J. (2010) · Heart · doi:10.1136/hrt.2010.210757 · Cited by 299
Corona, G., Maseroli, E., Rastrelli, G., Isidori, A. M., Sforza, A., Mannucci, E., & Maggi, M. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.950653 · Cited by 297
Testosterone: a vascular hormone in health and disease
Kelly, D. M., & Jones, T. H. (2013) · Journal of Endocrinology · doi:10.1530/joe-12-0582 · Cited by 301
Lowered testosterone in male obesity: Mechanisms, morbidity and management
Grossmann, M., Tang Fui, M., & Dupuis, P. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122365 · Cited by 293
High Serum Testosterone Is Associated With Reduced Risk of Cardiovascular Events in Elderly Men
Ohlsson, C., Barrett-Connor, E. L., Bhasin, S., ORWOLL, E. S., Labrie, F., Karlsson, M. K., Ljunggren, Ö., Vandenput, L., Mellström, D., & Tivesten, Å. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.07.019 · Cited by 298
Self-citationShaw, L., Blankstein, R., Bax, J., Ferencik, M., Bittencourt, M., Min, J., Berman, D., Leipsic, J., Villines, T., Dey, D., et al. (2020) · Journal of cardiovascular computed tomography · doi:10.1016/j.jcct.2020.11.002 · Cited by 250
New horizons in the pathogenesis, diagnosis and management of sarcopenia
Sayer, A. A., Robinson, S. M., Patel, H. P., Shavlakadze, T., Cooper, C., & Grounds, M. D. (2013) · Age and Ageing · doi:10.1093/ageing/afs191 · Cited by 290
Buvat, J., Maggi, M., Guay, A. T., & Torres, L. O. (2012) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02783.x · Cited by 285
Lessons From the Testosterone Trials
Snyder, P. J., Bhasin, S., Cunningham, G. R., Matsumoto, A. M., Stephens-Shields, A. J., Cauley, J. A., Gill, T. M., Barrett-Connor, E., Swerdloff, R. S., Wang, C., et al. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00234 · Cited by 280
Self-citationSarcopenia, osteoporosis and frailty
Gielen, E., Dupont, J., Dejaeger, M., & Laurent, M. R. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155638 · Cited by 282
Frailty and the endocrine system
Clegg, A. P., & Hassan-Smith, Z. K. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30110-4 · Cited by 278
Testosterone therapy for transgender men
Irwig, M. S. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00036-x · Cited by 272
Basaria, S., Harman, S. M., Travison, T. G., Hodis, H., Tsitouras, P., Budoff, M., Pencina, K. M., Vita, J., Dzekov, C., Mazer, N. A., et al. (2015) · JAMA · doi:10.1001/jama.2015.8881 · Cited by 268
Self-citationNeuroinflammation and Cerebrovascular Disease in Old Age: A Translational Medicine Perspective
Napoli, M. D., & Shah, I. M. (2011) · Journal of Aging Research · doi:10.4061/2011/857484 · Cited by 262
Handelsman, D. J. (2013) · Medical Journal of Australia · doi:10.5694/mja13.10111 · Cited by 253
Sarcopenia and menopause: The role of estradiol
Geraci, A., Calvani, R., Ferri, E., Marzetti, E., Arosio, B., & Cesari, M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.682012 · Cited by 238
Galloway, T. S., Cipelli, R., Guralnik, J. M., Ferrucci, L., Bandinelli, S., Corsi, A. M., Money, C., McCormack, P., & Melzer, D. R. (2010) · Environmental Health Perspectives · doi:10.1289/ehp.1002367 · Cited by 241
Onset of effects of testosterone treatment and time span until maximum effects are achieved
Saad, F., Aversa, A., Isidori, A. M., Zafalon, L., Zitzmann, M., & Gooren, L. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0221 · Cited by 232
Frailty and chronic kidney disease: current evidence and continuing uncertainties
Nixon, A. C., Bampouras, T. M., Pendleton, N., Woywodt, A., Mitra, S., & Dhaygude, A. P. (2017) · Clinical Kidney Journal · doi:10.1093/ckj/sfx134 · Cited by 239
Testosterone and the Cardiovascular System: A Comprehensive Review of the Clinical Literature
Oskui, P. M., French, W. J., Herring, M. J., Mayeda, G. S., Burstein, S., & Kloner, R. A. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000272 · Cited by 230
Genetic determinants of serum testosterone concentrations in men
Ohlsson, C., Wallaschofski, H., Lunetta, K. L., Stolk, L., Perry, J. R. B., Koster, A., Petersen, A.-K., Eriksson, J., Lehtimäki, T., Huhtaniemi, I. T., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002313 · Cited by 224
Self-citationSex Differences in Muscle Wasting
Anderson, L. J., Liu, H. M., & Garcia, J. M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-70178-3_9 · Cited by 226
Schooling, C. M., Yeung, S. L. A., Freeman, G., & Cowling, B. J. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-57 · Cited by 215
Wang, Y., O'Neil, A. E., Jiao, Y., Wang, L., Huang, J., Lan, Y., Zhu, Y., & Yu, C. (2019) · BMC Medicine · doi:10.1186/s12916-019-1355-0 · Cited by 213
Testosterone Therapy and Cardiovascular Risk: Advances and Controversies
Morgentaler, A., Miner, M. M., Caliber, M., Guay, A. T., Khera, M., & Traish, A. M. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.10.011 · Cited by 213
Sex hormones in the cardiovascular system
dos Santos, R. L., da Silva, F. B., Júnior, R. F. R., & Stefanon, I. (2014) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2013-0048 · Cited by 211
Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications
Pataky, M. W., Young, W. F., & Nair, K. S. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.07.033 · Cited by 207
Risk of Myocardial Infarction in Older Men Receiving Testosterone Therapy
Baillargeon, J., Urban, R. J., Kuo, Y., Ottenbacher, K. J., Raji, M. A., Du, F., Lin, Y., & Goodwin, J. S. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014539918 · Cited by 206
Traish, A. M., Miner, M. M., Morgentaler, A., & Zitzmann, M. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.12.027 · Cited by 206
Late-onset hypogonadism: Current concepts and controversies of pathogenesis, diagnosis and treatment
Huhtaniemi, I. T. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122336 · Cited by 203
Muscle metabolism and atrophy: let’s talk about sex
Rosa-Caldwell, M. E., & Greene, N. P. (2019) · Biology of Sex Differences · doi:10.1186/s13293-019-0257-3 · Cited by 202
Hunt, P. A., Sathyanarayana, S., Fowler, P., & Trasande, L. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2873 · Cited by 205
Testosterone Supplementation in Heart Failure
Toma, M., McAlister, F. A., Coglianese, E. E., Vidi, V. D., Vasaiwala, S. C., Bakal, J. A., Armstrong, P. W., & Ezekowitz, J. A. (2012) · Circulation Heart Failure · doi:10.1161/circheartfailure.111.965632 · Cited by 197
Erectile dysfunction in the cardiovascular patient
Vlachopoulos, C., Jackson, G. S., Stefanadis, C., & Montorsi, P. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht112 · Cited by 199
Gender-affirming hormones and surgery in transgender children and adolescents
Mahfouda, S., Moore, J. K., Siafarikas, A., Hewitt, T., Ganti, U., Lin, A. P., & Zepf, F. D. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30305-x · Cited by 197
Testosterone replacement therapy and cardiovascular risk
Gagliano‐Jucá, T., & Basaria, S. S. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0211-4 · Cited by 200
Self-citationCurrent and investigational medications for the treatment of sarcopenia
Rolland, Y., Dray, C., Vellas, B., & Barreto, P. D. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155597 · Cited by 195
Testosterone Lab Testing and Initiation in the United Kingdom and the United States, 2000 to 2011
Layton, J. B., Li, D., Meier, C. R., Sharpless, J. L., Stürmer, T., Jick, S. S., & Brookhart, M. A. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3570 · Cited by 197
The effects of oestrogens and their receptors on cardiometabolic health
Morselli, E., Santos, R. D. S., Criollo, A., Nelson, M. D., Palmer, B. F., & Clegg, D. J. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.12 · Cited by 195
Yeap, B. B., Alfonso, H. S., Chubb, S. A. P., Handelsman, D. J., Hankey, G. J., Almeida, O. P., Golledge, J., Norman, P. E., & Flicker, L. A. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3272 · Cited by 188
Hackett, G., Cole, N., Bhartia, M., Kennedy, D., Raju, J., & Wilkinson, P. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12146 · Cited by 182
Testosterone treatment and risk of venous thromboembolism: population based case-control study
Martinez, C., Suissa, S., Rietbrock, S., Katholing, A., Freedman, B., Cohen, A. T., & Handelsman, D. J. (2016) · BMJ · doi:10.1136/bmj.i5968 · Cited by 181
Hyde, Z., Norman, P. E., Flicker, L. A., Hankey, G. J., Almeida, O. P., McCaul, K. A., Chubb, S. A. P., & Yeap, B. B. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1617 · Cited by 181
Endocrinology of the aging male
de Araújo, A. B., & Wittert, G. (2011) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.11.004 · Cited by 184
Hauser, R. B., Skakkebæk, N. E., Hass, U., Toppari, J., Juul, A., Andersson, A., Kortenkamp, A., Heindel, J. J., & Trasande, L. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4325 · Cited by 189
Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men
Walther, A., Breidenstein, J., & Miller, R. E. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.2734 · Cited by 182
Rooks, D., Swan, T., Goswami, B., Filosa, L. A., Bunte, O., Panchaud, N., Coleman, L. A., Miller, R. R., Garcia Garayoa, E., Praestgaard, J., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.20836 · Cited by 177
Khera, M., Adaikan, G., Buvat, J., Carrier, S., El-Meliegy, A., Hatzimouratidis, K., McCullough, A., Morgentaler, A., Torres, L. O., & Salonia, A. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.10.009 · Cited by 177
Salonia, A., Burnett, A. L. “., Graefen, M., Hatzimouratidis, K., Montorsi, F., Mulhall, J. P., & Stief, C. G. (2012) · European Urology · doi:10.1016/j.eururo.2012.04.047 · Cited by 175
Storer, T. W., Basaria, S., Traustadottir, T., Harman, S. M., Pencina, K., Li, Z., Travison, T. G., Miciek, R., Tsitouras, P., Hally, K., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2771 · Cited by 174
Self-citationZarotsky, V., Huang, M., Carman, W. J., Morgentaler, A., Singhal, P. K., Coffin, D., & Jones, T. H. (2014) · Andrology · doi:10.1111/andr.274 · Cited by 178
Cheetham, T. C., An, J., Jacobsen, S. J., Niu, F., Sidney, S., Quesenberry, C. P., & Eeden, S. K. V. D. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.9546 · Cited by 173
Carson, J. A., & Manolagas, S. C. (2015) · Bone · doi:10.1016/j.bone.2015.04.015 · Cited by 173
Erythrocytosis Following Testosterone Therapy
Ohlander, S. J., Varghese, B., & Pastuszak, A. W. (2018) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2017.04.001 · Cited by 168
Hackett, G., Cole, N., Bhartia, M., Kennedy, D., Raju, J., Wilkinson, P., & the BLAST Study Group (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12404 · Cited by 168
Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs
Terentes-Printzios, D. G., Ioakeimidis, N., Rokkas, K., & Vlachopoulos, C. V. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00593-6 · Cited by 172
Jaruvongvanich, V., Sanguankeo, A., Riangwiwat, T., & Upala, S. (2017) · Annals of Hepatology · doi:10.5604/01.3001.0009.8593 · Cited by 170
Metadata
- Authors
- Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., Choong, K., Lakshman, K. M., Mazer, N. A., Miciek, R., Krasnoff, J., Elmi, A., Knapp, P. E., Brooks, B., Appleman, E., Aggarwal, S., Bhasin, G., Hede-Brierley, L., Bhatia, A., Collins, L., LeBrasseur, N., Fiore, L. D., & Bhasin, S.
- Affiliations
- Boston University (US)
- Brigham and Women's Hospital (US)
- New England Research Institutes (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-07-08
- Volume
- 363
- Issue
- 2
- Pages
- 109-122
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3440621
- OpenAlex
- W2155877918
- Cited by
- 1,494
- References
- 56
- Citations by year
- 2026: 33 · 2025: 52 · 2024: 68 · 2023: 63 · 2022: 76 · 2021: 66 · 2020: 91 · 2019: 65 · 2018: 92 · 2017: 132 · 2016: 103 · 2015: 122 · 2014: 169 · 2013: 96 · 2012: 108
- FWCI
- 85.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health (5p30ag031679-15)
- National Institute on Aging (U01AG014369, R01AG037193, 5 P30 AG031679, P30-AG031679, 1UO1AG14369)
- National Center for Research Resources (UL1RR025771)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- testosterone replacement therapy, testosterone gel, adverse events, cardiovascular events, older men, mobility limitations, hypogonadism, muscle strength, trial discontinuation, drug safety
- MeSH terms
- Administration, Cutaneous, Aged, Aged, 80 and over, Cardiovascular Diseases, Double-Blind Method, Exercise Test, Gels, Humans, Hyperlipidemias, Hypertension, Male, Obesity, Risk Factors, Testosterone, Logistic Models, Walking, Kaplan-Meier Estimate, Muscle Strength
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
